CN115247025A - 一种硅凝胶膜及其制备方法 - Google Patents
一种硅凝胶膜及其制备方法 Download PDFInfo
- Publication number
- CN115247025A CN115247025A CN202210944096.1A CN202210944096A CN115247025A CN 115247025 A CN115247025 A CN 115247025A CN 202210944096 A CN202210944096 A CN 202210944096A CN 115247025 A CN115247025 A CN 115247025A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- gel film
- silicone gel
- polydimethylsiloxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010025899 gelatin film Proteins 0.000 title claims abstract description 43
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 title abstract description 12
- 229910052710 silicon Inorganic materials 0.000 title abstract description 12
- 239000010703 silicon Substances 0.000 title abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 118
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 41
- 239000002250 absorbent Substances 0.000 claims abstract description 40
- 230000002745 absorbent Effects 0.000 claims abstract description 40
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 38
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 38
- -1 polydimethylsiloxane Polymers 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 37
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 35
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims abstract description 31
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000005058 Isophorone diisocyanate Substances 0.000 claims abstract description 31
- 239000003054 catalyst Substances 0.000 claims abstract description 31
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000002994 raw material Substances 0.000 claims abstract description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 61
- 239000000741 silica gel Substances 0.000 claims description 61
- 229910002027 silica gel Inorganic materials 0.000 claims description 61
- 238000010438 heat treatment Methods 0.000 claims description 30
- 238000001816 cooling Methods 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 13
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 13
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims description 13
- 206010004542 Bezoar Diseases 0.000 claims description 13
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 13
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims description 13
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical group CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 claims description 13
- 229940116229 borneol Drugs 0.000 claims description 13
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 13
- 239000012975 dibutyltin dilaurate Substances 0.000 claims description 13
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 13
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- 229960003128 mupirocin Drugs 0.000 claims description 13
- 229930187697 mupirocin Natural products 0.000 claims description 13
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical group O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims description 13
- 244000131316 Panax pseudoginseng Species 0.000 claims description 12
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 12
- 229940056582 human hair preparation Drugs 0.000 claims description 12
- 241000405911 Rehmannia glutinosa Species 0.000 claims description 11
- 229920000609 methyl cellulose Polymers 0.000 claims description 10
- 239000001923 methylcellulose Substances 0.000 claims description 10
- 235000010981 methylcellulose Nutrition 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 229960001631 carbomer Drugs 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 239000000661 sodium alginate Substances 0.000 claims description 5
- 235000010413 sodium alginate Nutrition 0.000 claims description 5
- 229940005550 sodium alginate Drugs 0.000 claims description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 5
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 4
- 239000012676 herbal extract Substances 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 239000004745 nonwoven fabric Substances 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 240000007890 Leonurus cardiaca Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 61
- 206010052428 Wound Diseases 0.000 abstract description 59
- 238000011084 recovery Methods 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 13
- 230000000740 bleeding effect Effects 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 230000029663 wound healing Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 208000035143 Bacterial infection Diseases 0.000 abstract description 5
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 230000003467 diminishing effect Effects 0.000 abstract description 4
- 210000000416 exudates and transudate Anatomy 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 22
- 239000000499 gel Substances 0.000 description 15
- 241000207925 Leonurus Species 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000035699 permeability Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002313 adhesive film Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000003376 silicon Polymers 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 239000009277 Panax notoginseng extract Substances 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D175/00—Coating compositions based on polyureas or polyurethanes; Coating compositions based on derivatives of such polymers
- C09D175/04—Polyurethanes
- C09D175/14—Polyurethanes having carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/61—Polysiloxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/67—Unsaturated compounds having active hydrogen
- C08G18/671—Unsaturated compounds having only one group containing active hydrogen
- C08G18/672—Esters of acrylic or alkyl acrylic acid having only one group containing active hydrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
- C08G18/75—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
- C08G18/751—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring
- C08G18/752—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group
- C08G18/753—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group containing one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group having a primary carbon atom next to the isocyanate or isothiocyanate group
- C08G18/755—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring containing at least one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group containing one isocyanate or isothiocyanate group linked to the cycloaliphatic ring by means of an aliphatic group having a primary carbon atom next to the isocyanate or isothiocyanate group and at least one isocyanate or isothiocyanate group linked to a secondary carbon atom of the cycloaliphatic ring, e.g. isophorone diisocyanate
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D7/00—Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
- C09D7/40—Additives
- C09D7/60—Additives non-macromolecular
- C09D7/63—Additives non-macromolecular organic
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D7/00—Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
- C09D7/40—Additives
- C09D7/65—Additives macromolecular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提出了一种硅凝胶膜及其制备方法,涉及硅凝胶膜制造技术领域。一种硅凝胶膜,按重量份计,包括如下原料:聚二甲基硅氧烷90‑110份、异佛尔酮二异氰酸酯15‑30份、甲基丙烯酸羟乙酯10‑15份、中药提取物10‑20份、催化剂0.3‑0.5份、吸水剂5‑10份和抗菌剂1‑3份。本发明通过聚二甲基硅氧烷与其余物质反应,能够利用其较好的透气性能,制备成透气的硅凝胶,而中药提取物能够起到良好的止血消炎和促进伤口愈合的效果,其被包裹在硅凝胶中,能够缓慢释放,从而长效起效;而吸水剂能够有效的吸附伤口的渗出液,保持创口干燥,提供一个利于创面恢复的环境;抗菌剂能够对创面进行杀菌,防细菌感染,加速创面恢复。
Description
技术领域
本发明涉及硅凝胶膜制造技术领域,具体而言,涉及一种硅凝胶膜及其制备方法。
背景技术
皮肤是人体的最大器官,是维持体内环境稳定和阻止微生物入侵的天然屏障;然而,大面积暴露于外界的特点,使得皮肤很容易受到烧伤、机械伤等外来伤害,则会引起许多局部甚至全身性问题,如新陈代谢加剧、水分和蛋白质过度散失、免疫***失调等,严重的还会危及生命。若创面覆盖适当的膜,能有效降低患者机体超高代谢的严重程度,减轻疼痛,防止细菌感染,加速创面愈合。
烧伤、创伤或外科手术后,在病人体表会形成创口,创口的恢复常常受到创口环境的影响,如果创口环境有害杂菌或污染多,会导致创口反复发炎,不能及时恢复,还会在创口形成瘢痕,影响外观容貌。为了使得创口获得良好的恢复,国外发明了将硅凝胶做成硅凝胶贴膜后达到了预期效果,国内最早于1997开始也试制成功了硅凝胶贴膜。
硅凝胶膜是根据其孔径的大小分为:大孔硅胶、粗孔硅胶、B型硅胶、细孔硅胶,由于孔隙结构的不同,因此它们的吸附性能各有特点。粗孔硅胶在相对湿度高的情况下有较高的吸附量,细孔硅胶则在相对湿度较低的情况下吸附量高于粗孔硅胶,而B型硅胶由于孔结构介于粗、细孔之间,其吸附量也介于粗、细孔之间,硅凝胶和硅凝胶膜具有良好的生物相容性,对人体组织无刺激性、无毒性、无过敏反应、机体排异反应极少;具有良好的理化特性,与体液以及组织接触过程中能保持其原有的弹性和柔软度,是一种相当稳定的惰性物质,能耐高温,可消毒,加工成型方便,易加工雕刻形状,使用方便其用途,主要为医用硅胶。
但是,现有的硅凝胶膜存在吸水性差和水汽透过性差的问题,在将其贴附于创口时,如果组织液比较多,就会渗出,导致伤口恢复情况差和创口发白的问题;此外,大多的硅凝胶膜只能起到隔离的作用,对于伤口的恢复只能依靠人体自身免疫力,使得恢复较慢。
发明内容
本发明的目的在于提供一种硅凝胶膜,此硅凝胶膜具有吸水性好和水汽透过性好的优点,还能够加快伤口恢复。
本发明的另一目的在于提供一种硅凝胶膜的制备方法,以获得此硅凝胶膜。
本发明解决其技术问题是采用以下技术方案来实现的。
一方面,本申请实施例提供一种硅凝胶膜,按重量份计,包括如下原料:
聚二甲基硅氧烷90-110份、异佛尔酮二异氰酸酯15-30份、甲基丙烯酸羟乙酯10-15份、中药提取物10-20份、催化剂0.3-0.5份、吸水剂5-10份和抗菌剂1-3份。
另一方面,本申请实施例提供一种硅凝胶膜的制备方法,包括如下步骤:
将聚二甲基硅氧烷加热2-3h,再降温至50-55℃,加入异佛尔酮二异氰酸酯,加热3-5h,降温至50-55℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应后,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
相对于现有技术,本发明的实施例至少具有如下优点或有益效果:
本发明通过聚二甲基硅氧烷与其余物质反应,能够利用其较好的透气性能,制备成透气的硅凝胶,而中药提取物能够起到良好的止血消炎和促进伤口愈合的效果,其被包裹在硅凝胶中,能够缓慢释放,从而长效起效;而吸水剂能够有效的吸附伤口的渗出液,保持创口干燥,提供一个利于创面恢复的环境;抗菌剂能够对创面进行杀菌,防止细菌感染,能够加速创面恢复。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
需要说明的是,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。下面将参考具体实施例来详细说明本发明。
本发明提供一种硅凝胶膜,按重量份计,包括如下原料:
聚二甲基硅氧烷90-110份、异佛尔酮二异氰酸酯15-30份、甲基丙烯酸羟乙酯10-15份、中药提取物10-20份、催化剂0.3-0.5份、吸水剂5-10份和抗菌剂1-3份。本发明通过聚二甲基硅氧烷与其余物质反应,能够利用其较好的透气性能,制备成透气的硅凝胶,而中药提取物能够起到良好的止血消炎和促进伤口愈合的效果,其被包裹在硅凝胶中,能够缓慢释放,从而长效起效;而吸水剂能够有效的吸附伤口的渗出液,保持创口干燥,提供一个利于创面恢复的环境;抗菌剂能够对创面进行杀菌,防止细菌感染,能够加速创面恢复。
在本发明的一些实施例中,上述催化剂为二月桂酸二丁基锡。其能够有效加快反应,提高效率。
在本发明的一些实施例中,上述中药提取物为血余提取物2-4份、石决明提取物1-2份、地黄提取物2-4份、三七提取物1-3份、茺蔚子提取物2-3份、冰片提取物1.5-3份和牛黄提取物0.5-1份。血余具有止血、化瘀和抑菌之效;石决明具有收敛止血和制酸止痛之效;地黄能够止血凉血,促进创口恢复;三七具有化瘀止血和活血定痛之效;茺蔚子具有活血调经之效;冰片具有开窍醒神和清热止痛之效;牛黄具有凉肝息风和清热解毒之效。而在诸药混合后包裹在凝胶中,能够协同缓慢作用于创面,起到促进创面愈合和止痛之效。
在本发明的一些实施例中,上述吸水剂为甲基纤维素、羟乙基纤维素、卡波姆、透明质酸钠和海藻酸钠中的一种。甲基纤维素为亲水胶体,具有良好的吸水性,其无毒无刺激。羟乙基纤维素属于水溶性非离子型化合物,对水有良好的稠化能力,具有增稠、乳化、粘合、悬浮、成膜、保持水分及保护胶体等性能。卡波姆是最有效的水溶性增稠剂,能够有效吸湿。透明质酸钠具有突出的吸湿性能,能够有效吸水膨胀,且还具有促进创口愈合的作用,能够在组织表面形成大分子网状屏障,阻止污染物进入创面,其还具有比较好的粘附力,能够使得药物长久留存在创面表面,促进创面吸收药效,加快创面愈合。海藻酸钠易于凝胶化,能够有效止血,其同样具有良好的吸水性能。
在本发明的一些实施例中,上述抗菌剂为莫匹罗星或醋酸曲安奈德。莫匹罗星是一种局部外用抗生素,主要通过可逆性地与异亮氨酸转移RNA合成酶结合,阻止异亮氨酸掺入,终止细胞内含异亮氨酸的蛋白质合成,导致细菌死亡,其在低浓度时有抑制作用,高浓度时有杀菌作用。其对与皮肤感染有关的各种革兰阳性球菌,尤其是葡萄球菌(包括耐药金黄色葡萄球菌)、化脓性链球菌高度敏感;对单核细胞增生性李斯特菌及红斑丹毒丝菌也有效;对革兰阴性菌一般不敏感,但对某些革兰阴性菌如大肠杆菌、奈瑟菌属、流感嗜血杆菌和***具有一定的抗菌作用。醋酸曲安奈德为糖皮质激素,能够减轻和防止组织对炎症的反应,从而减轻炎症的表现,可以防止或抑制细胞中介的免疫反应,延迟性的过敏反应。
本发明还提供一种硅凝胶膜的制备方法,包括如下步骤:
将聚二甲基硅氧烷加热2-3h,再降温至50-55℃,加入异佛尔酮二异氰酸酯,加热3-5h,降温至50-55℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应后,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。该制备方法简单便捷,能够生产出治疗效果好,促进创面愈合快的硅凝胶膜。
在本发明的一些实施例中,上述防黏膜为无纺布、PE膜、PU膜、棉布、弹力布和丝绸中的任意一种。
在本发明的一些实施例中,上述聚二甲基硅氧烷加热的温度条件为95-110℃、真空度条件为0.1-0.18MPa。
在本发明的一些实施例中,上述异佛尔酮二异氰酸酯后加热温度为85-95℃。
在本发明的一些实施例中,上述加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂后,反应时间为20-30h。充分反应,能够使得各个物质分散均匀,使得其品质均衡。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷90g、异佛尔酮二异氰酸酯15g、甲基丙烯酸羟乙酯10g、中药提取物(血余提取物2g、石决明提取物1g、地黄提取物2g、三七提取物1g、茺蔚子提取物2g、冰片提取物1.5g和牛黄提取物0.5g)10g、催化剂(二月桂酸二丁基锡)0.3g、吸水剂(甲基纤维素)5g和抗菌剂(莫匹罗星)1g;
将聚二甲基硅氧烷在温度为95℃、真空度为0.1MPa条件下加热2-3h,再降温至50℃,加入异佛尔酮二异氰酸酯,在85℃下加热3h,降温至50℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应20h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
实施例2
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷95g、异佛尔酮二异氰酸酯20g、甲基丙烯酸羟乙酯12g、中药提取物(血余提取物3g、石决明提取物1g、地黄提取物2g、三七提取物2g、茺蔚子提取物2.5g、冰片提取物2g和牛黄提取物0.8g)13.3g、催化剂(二月桂酸二丁基锡)0.4g、吸水剂(甲基纤维素)6g和抗菌剂(莫匹罗星)1.5g;
将聚二甲基硅氧烷在温度为100℃、真空度为0.12MPa条件下加热2.5h,再降温至51℃,加入异佛尔酮二异氰酸酯,在90℃下加热4h,降温至51℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应22h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
实施例3
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷100g、异佛尔酮二异氰酸酯25g、甲基丙烯酸羟乙酯13g、中药提取物(血余提取物3g、石决明提取物1.5g、地黄提取物3g、三七提取物2g、茺蔚子提取物2.5g、冰片提取物2.5g和牛黄提取物0.8g)15.3g、催化剂(二月桂酸二丁基锡)0.4g、吸水剂(甲基纤维素)8g和抗菌剂(莫匹罗星)2g;
将聚二甲基硅氧烷在温度为105℃、真空度为0.14MPa条件下加热2.5h,再降温至53℃,加入异佛尔酮二异氰酸酯,在90℃下加热4h,降温至53℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应25h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
实施例4
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷105g、异佛尔酮二异氰酸酯28g、甲基丙烯酸羟乙酯14g、中药提取物(血余提取物3.5g、石决明提取物1.8g、地黄提取物3.5g、三七提取物2.5g、茺蔚子提取物2.8g、冰片提取物2.8g和牛黄提取物0.9g)10-20g、催化剂(二月桂酸二丁基锡)0.5g、吸水剂(甲基纤维素)9g和抗菌剂(莫匹罗星)2.5g;
将聚二甲基硅氧烷在温度为110℃、真空度为0.16MPa条件下加热2.8h,再降温至54℃,加入异佛尔酮二异氰酸酯,在93℃下加热4.5h,降温至54℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应28h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
实施例5
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷110g、异佛尔酮二异氰酸酯30g、甲基丙烯酸羟乙酯15g、中药提取物(血余提取物4g、石决明提取物2g、地黄提取物4g、三七提取物3g、茺蔚子提取物3g、冰片提取物3g和牛黄提取物1g)20g、催化剂(二月桂酸二丁基锡)0.5g、吸水剂(甲基纤维素)5-10g和抗菌剂(莫匹罗星)3g;
将聚二甲基硅氧烷在温度为110℃、真空度为0.18MPa条件下加热3h,再降温至55℃,加入异佛尔酮二异氰酸酯,在95℃下加热5h,降温至55℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应30h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
对比例1
本对比例与实施例3基本相同,区别在于:未添加中药提取物。
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷100g、异佛尔酮二异氰酸酯25g、甲基丙烯酸羟乙酯13g、催化剂(二月桂酸二丁基锡)0.4g、吸水剂(甲基纤维素)8g和抗菌剂(莫匹罗星)2g;
将聚二甲基硅氧烷在温度为105℃、真空度为0.14MPa条件下加热2.5h,再降温至53℃,加入异佛尔酮二异氰酸酯,在90℃下加热4h,降温至53℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、吸水剂和抗菌剂,反应25h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
对比例2
本对比例与实施例3基本相同,区别在于:吸水剂为羟乙基纤维素。
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷100g、异佛尔酮二异氰酸酯25g、甲基丙烯酸羟乙酯13g、中药提取物(血余提取物3g、石决明提取物1.5g、地黄提取物3g、三七提取物2g、茺蔚子提取物2.5g、冰片提取物2.5g和牛黄提取物0.8g)15.3g、催化剂(二月桂酸二丁基锡)0.4g、吸水剂(羟乙基纤维素)8g和抗菌剂(莫匹罗星)2g;
将聚二甲基硅氧烷在温度为105℃、真空度为0.14MPa条件下加热2.5h,再降温至53℃,加入异佛尔酮二异氰酸酯,在90℃下加热4h,降温至53℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应25h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
对比例3
本对比例与实施例3基本相同,区别在于:吸水剂为卡波姆。
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷100g、异佛尔酮二异氰酸酯25g、甲基丙烯酸羟乙酯13g、中药提取物(血余提取物3g、石决明提取物1.5g、地黄提取物3g、三七提取物2g、茺蔚子提取物2.5g、冰片提取物2.5g和牛黄提取物0.8g)15.3g、催化剂(二月桂酸二丁基锡)0.4g、吸水剂(卡波姆)8g和抗菌剂(莫匹罗星)2g;
将聚二甲基硅氧烷在温度为105℃、真空度为0.14MPa条件下加热2.5h,再降温至53℃,加入异佛尔酮二异氰酸酯,在90℃下加热4h,降温至53℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应25h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
对比例4
本对比例与实施例3基本相同,区别在于:吸水剂为透明质酸钠。
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷100g、异佛尔酮二异氰酸酯25g、甲基丙烯酸羟乙酯13g、中药提取物(血余提取物3g、石决明提取物1.5g、地黄提取物3g、三七提取物2g、茺蔚子提取物2.5g、冰片提取物2.5g和牛黄提取物0.8g)15.3g、催化剂(二月桂酸二丁基锡)0.4g、吸水剂(透明质酸钠)8g和抗菌剂(莫匹罗星)2g;
将聚二甲基硅氧烷在温度为105℃、真空度为0.14MPa条件下加热2.5h,再降温至53℃,加入异佛尔酮二异氰酸酯,在90℃下加热4h,降温至53℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应25h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
对比例5
本对比例与实施例3基本相同,区别在于:吸水剂为海藻酸钠。
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷100g、异佛尔酮二异氰酸酯25g、甲基丙烯酸羟乙酯13g、中药提取物(血余提取物3g、石决明提取物1.5g、地黄提取物3g、三七提取物2g、茺蔚子提取物2.5g、冰片提取物2.5g和牛黄提取物0.8g)15.3g、催化剂(二月桂酸二丁基锡)0.4g、吸水剂(海藻酸钠)8g和抗菌剂(莫匹罗星)2g;
将聚二甲基硅氧烷在温度为105℃、真空度为0.14MPa条件下加热2.5h,再降温至53℃,加入异佛尔酮二异氰酸酯,在90℃下加热4h,降温至53℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应25h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
对比例6
本对比例与实施例3基本相同,区别在于:抗菌剂为醋酸曲安奈德。
一种硅凝胶膜的制备方法,包括如下步骤:
原料:聚二甲基硅氧烷100g、异佛尔酮二异氰酸酯25g、甲基丙烯酸羟乙酯13g、中药提取物(血余提取物3g、石决明提取物1.5g、地黄提取物3g、三七提取物2g、茺蔚子提取物2.5g、冰片提取物2.5g和牛黄提取物0.8g)15.3g、催化剂(二月桂酸二丁基锡)0.4g、吸水剂(甲基纤维素)8g和抗菌剂(醋酸曲安奈德)2g;
将聚二甲基硅氧烷在温度为105℃、真空度为0.14MPa条件下加热2.5h,再降温至53℃,加入异佛尔酮二异氰酸酯,在90℃下加热4h,降温至53℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应25h,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
实验例
一、创面愈合实验
选用44只体重在2±0.2kg的白色家兔,应用成年、健康且皮肤无损伤的动物,雌性和雄性各一半,在实验前将家兔适应性喂养7天,将家兔随机分为11组,每组4只,分别用于实施例1-5和对比例1-6制备的硅凝胶膜实验。
实验过程中将白色家兔脊柱两侧的脱毛处理,脱毛面积为3cm×3cm,用手术刀在白色家兔脱毛处划2cm×2cm大小的“#”,制造出血创面,一侧为实验组,用创面用硅凝胶膜进行覆盖;另一侧为对照组,创面不做任何处理,仅用纱布覆盖。
间隔30s观察创面出血情况,记录停止流血时间,具体结果如表1所示。
表1
分析表1,可以看出,实施例和对比例的实验组的止血时间均短于对照组的止血时间,这说明本申请制备的硅凝胶膜能促进创面止血。
对比实施例1-5,可以看出,实施例3的创面止血时间最短,这说明实施例3的硅凝胶膜的效果最佳。
对比实施例3和对比例1,可以看出,中药提取物能够有效的提高创面止血愈合的速度,能够促进创面愈合;对比例实施例3和对比例2-5,可以看出,吸水剂为卡波姆对创面愈合更好,这可能是由于卡波姆的吸水效果更好,能够给创面一个更好的恢复条件,促进创面愈合;对比实施例3和对比例6,可以看出,抗菌剂为醋酸曲安奈德对创面愈合更好。
二、透气情况测试
选用12只体重在2±0.2kg的白色家兔,应用成年、健康、皮肤无损伤的动物,雌性和雄性各一半,随机分为3组,每组4只,在实验前将家兔适应性喂养7天。
实验过程中将白色家兔脊柱一侧的脱毛处理,脱毛面积为3cm×3cm,用手术刀在白色家兔脱毛处划2cm×2cm大小的“#”,制造出血创面,每只家兔分别用实施例3、对比例3和对比例6进行覆盖,在24h和48h后分别观察创面情况,结果如表2所示。
创面情况分为良好、一般和较差。
良好:创面未泛白、红肿,恢复良好,已结痂。
一般:创面轻微泛白或轻微红肿,恢复比较好,已结痂。
较差:创面明显泛白、红肿,恢复较差,未结痂。
表2
试样 | 良好/只 | 一般/只 | 较差/只 |
实施例3 | 4 | 0 | 0 |
对比例3 | 4 | 0 | 0 |
对比例6 | 4 | 0 | 0 |
分析表2,可以看出,本申请制备的硅凝胶膜透气效果好,能够促进创面恢复。
综上所述,本发明通过聚二甲基硅氧烷与其余物质反应,能够利用其较好的透气性能,制备成透气的硅凝胶,而中药提取物能够起到良好的止血消炎和促进伤口愈合的效果,其被包裹在硅凝胶中,能够缓慢释放,从而长效起效;而吸水剂能够有效的吸附伤口的渗出液,保持创口干燥,提供一个利于创面恢复的环境;抗菌剂能够对创面进行杀菌,防止细菌感染,能够加速创面恢复。
以上所描述的实施例是本发明一部分实施例,而不是全部的实施例。本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
Claims (10)
1.一种硅凝胶膜,其特征在于,按重量份计,包括如下原料:
聚二甲基硅氧烷90-110份、异佛尔酮二异氰酸酯15-30份、甲基丙烯酸羟乙酯10-15份、中药提取物10-20份、催化剂0.3-0.5份、吸水剂5-10份和抗菌剂1-3份。
2.根据权利要求1所述的一种硅凝胶膜,其特征在于,所述催化剂为二月桂酸二丁基锡。
3.根据权利要求1所述的一种硅凝胶膜,其特征在于,所述中药提取物为血余提取物2-4份、石决明提取物1-2份、地黄提取物2-4份、三七提取物1-3份、茺蔚子提取物2-3份、冰片提取物1.5-3份和牛黄提取物0.5-1份。
4.根据权利要求1所述的一种硅凝胶膜,其特征在于,所述吸水剂为甲基纤维素、羟乙基纤维素、卡波姆、透明质酸钠和海藻酸钠中的一种。
5.根据权利要求1所述的一种硅凝胶膜,其特征在于,所述抗菌剂为莫匹罗星或醋酸曲安奈德。
6.如权利要求1-5任意一项所述的一种硅凝胶膜的制备方法,其特征在于,包括如下步骤:
将聚二甲基硅氧烷加热2-3h,再降温至50-55℃,加入异佛尔酮二异氰酸酯,加热3-5h,降温至50-55℃,再加入催化剂,搅拌均匀后,加入甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂,反应后,得到硅凝胶;
将硅凝胶涂覆于防黏膜上,得到硅凝胶膜成品。
7.根据权利要求6所述的一种硅凝胶膜,其特征在于,所述防黏膜为无纺布、PE膜、PU膜、棉布、弹力布和丝绸中的任意一种。
8.根据权利要求6所述的一种硅凝胶膜,其特征在于,所述聚二甲基硅氧烷加热的温度条件为95-110℃、真空度条件为0.1-0.18MPa。
9.根据权利要求6所述的一种硅凝胶膜,其特征在于,加入所述异佛尔酮二异氰酸酯后加热温度为85-95℃。
10.根据权利要求6所述的一种硅凝胶膜,其特征在于,加入所述甲基丙烯酸羟乙酯、中药提取物、吸水剂和抗菌剂后,反应时间为20-30h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210944096.1A CN115247025A (zh) | 2022-08-05 | 2022-08-05 | 一种硅凝胶膜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210944096.1A CN115247025A (zh) | 2022-08-05 | 2022-08-05 | 一种硅凝胶膜及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115247025A true CN115247025A (zh) | 2022-10-28 |
Family
ID=83699199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210944096.1A Pending CN115247025A (zh) | 2022-08-05 | 2022-08-05 | 一种硅凝胶膜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115247025A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201121581A (en) * | 2009-12-31 | 2011-07-01 | Modetex Biomedical Materials & Amp Technology Ind Corp | Pharmaceutical dosage form for treating, managing or preventing vaginal infections or cervical cancer and gel composition and hydrophilic foam comprised therein |
CN104927015A (zh) * | 2015-06-05 | 2015-09-23 | 武汉理工大学 | 有机硅修饰的脂肪族聚氨酯生物材料及其制备方法 |
CN105169137A (zh) * | 2015-10-23 | 2015-12-23 | 东莞市达庆医疗器械有限公司 | 一种抗过敏凝胶敷料及其制备方法 |
WO2016069396A2 (en) * | 2014-10-31 | 2016-05-06 | Lubrizol Advanced Materials, Inc. | Thermoplastic polyurethane film for delivery of active agents to skin surfaces |
CN109602941A (zh) * | 2018-11-27 | 2019-04-12 | 吉林大学 | 一种高氧气透过率水凝胶敷料及其制备方法 |
CN111388355A (zh) * | 2020-04-06 | 2020-07-10 | 华中科技大学同济医学院附属协和医院 | 一种用于阻隔病原体接触的皮肤防护剂及其制备方法 |
-
2022
- 2022-08-05 CN CN202210944096.1A patent/CN115247025A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201121581A (en) * | 2009-12-31 | 2011-07-01 | Modetex Biomedical Materials & Amp Technology Ind Corp | Pharmaceutical dosage form for treating, managing or preventing vaginal infections or cervical cancer and gel composition and hydrophilic foam comprised therein |
WO2016069396A2 (en) * | 2014-10-31 | 2016-05-06 | Lubrizol Advanced Materials, Inc. | Thermoplastic polyurethane film for delivery of active agents to skin surfaces |
CN104927015A (zh) * | 2015-06-05 | 2015-09-23 | 武汉理工大学 | 有机硅修饰的脂肪族聚氨酯生物材料及其制备方法 |
CN105169137A (zh) * | 2015-10-23 | 2015-12-23 | 东莞市达庆医疗器械有限公司 | 一种抗过敏凝胶敷料及其制备方法 |
CN109602941A (zh) * | 2018-11-27 | 2019-04-12 | 吉林大学 | 一种高氧气透过率水凝胶敷料及其制备方法 |
CN111388355A (zh) * | 2020-04-06 | 2020-07-10 | 华中科技大学同济医学院附属协和医院 | 一种用于阻隔病原体接触的皮肤防护剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108014366B (zh) | 一种海洋生物材料复合水凝胶敷料及其制备方法 | |
CN105012993A (zh) | 一种阳离子医用生物胶抗菌敷料及其制备方法 | |
CA2164624A1 (en) | Dried hydrogel from hydrophylic-hygroscopic polymer | |
CN110507845A (zh) | 生物复合透气敷料及其制备方法 | |
Khorasani et al. | The effects of Aloe Vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebo-controlled study | |
CN108452293A (zh) | 一种妇科用凝胶及其制备方法 | |
CN105169455B (zh) | 一种烧烫伤外用急救医用敷料及其制备方法 | |
CN112587655B (zh) | 一种用于烧伤的木立芦荟-壳聚糖-氧化石墨烯凝胶冻干粉 | |
CN108686103B (zh) | 一种止血中药组合物以及多功能紧急止血复合材料 | |
CN114343975A (zh) | 一种创面湿性敷料及其制备方法 | |
CN111012945B (zh) | 一种防水中药液体创可贴及其制备方法 | |
CN115247025A (zh) | 一种硅凝胶膜及其制备方法 | |
CN114848884B (zh) | 一种聚氨酯泡沫敷料及其制备方法 | |
CN109432483B (zh) | 一种加速创面愈合的医用敷料及其制备方法和应用 | |
RU2284824C1 (ru) | Клей хирургический антисептический "аргакол" | |
CN106729940B (zh) | 一种缓释型长效抗菌载银敷料及其制备方法 | |
CN113456735B (zh) | 一种灭活益生菌草本凝胶及其制备方法和应用 | |
CN112121146B (zh) | 一种用于皮肤创伤的外用凝胶剂及其制备方法 | |
RU2545729C1 (ru) | Сетчатое биоактивное раневое покрытие | |
CN113855849A (zh) | 一种敷料组合物及其制备方法和应用 | |
CN112023110A (zh) | 一类基于竹荪蛋提取物的活性抑菌敷料 | |
CN114306721B (zh) | 一种防水透气的泡沫敷料及其制备方法 | |
CN114685823B (zh) | 一种抗卷曲壳聚糖水凝胶膜及其制备方法和慢性伤口敷料 | |
CN115089562B (zh) | 一种抗菌医用疤痕贴及其制备方法 | |
CN114931594B (zh) | 一种用于***止血止痛的软膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221028 |